Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-β1-induced kidney disease

Kidney International

Volumn 68, Issue 6, 2005, Pages 2651-2666

  Krag, Søren ^a   Danielsen, Carl Christian ^b   Carmeliet, Peter ^b   Nyengaard, Jens ^b   Wogensen, Lise ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

Kidney fibrosis; PAI 1; TGF 1

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GELATIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; GLOMERULOPATHY; GLOMERULUS; GLOMERULUS BASEMENT MEMBRANE; HISTOPATHOLOGY; IN VIVO STUDY; KIDNEY DISEASE; KIDNEY INTERSTITIUM; KNOCKOUT GENE; KNOCKOUT MOUSE; MALE; MESANGIUM; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEFICIENCY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSGENIC MOUSE; ZYMOGRAPHY;

ANIMALS; BASEMENT MEMBRANE; BODY WEIGHT; COLLAGEN; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; FIBRONECTINS; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; MACROPHAGES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; ORGAN SIZE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 32844468585     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00737.x     Document Type: Article

References (44)

1. YAMAMOTO T, NAKAMURA T, NOBLE NA, et al: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 90:1814-1818, 1993
2. NAKAMURA T, EBIHARA I, FUKUI M, et al: Messenger RNA expression for growth factors in glomeruli from focal glomerular sclerosis. Clin Immunol Immunopathol 66:33-12, 1993
3. YOSHIOKA K, TAKEMURA T, MURAKAMI K, et al: Transforming growth factor-beta protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 68:154-163, 1993
4. CHENG J, GRANDE JP: Transforming growth factor-beta signal transduction and progressive renal disease. Exp Biol Med (Maywood) 227:943-956, 2002
5. WOGENSEN L, NIELSEN CB, HJORTH P, et al: Under control of the Ren-1c promoter, locally produced transforming growth factor-beta1 induces accumulation of glomerular extracellular matrix in transgenic mice. Diabetes 48:182-192, 1999
6. KRAG S, OSTERBY R, CHAI Q, et al: TGF-beta1-induced glomerular disorder is associated with impaired concentrating ability mimicking primary glomerular disease with renal failure in man. Lab Invest 80:1855-1868, 2000
7. CHAI Q, KRAG S, CHAI S, et al: Localisation and phenotypical characterisation of collagen-producing cells in TGF-beta 1-induced renal interstitial fibrosis. Histochem Cell Biol 119:267-280, 2003
8. ROBERTS AB: Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 24:111-119, 1998
9. NAKAMURA T, MILLER D, RUOSLAHTI E, et al: Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1. Kidney Int 41:1213-1221, 1992
10. CREELY JJ, DIMARI SJ, HOWE AM, et al: Effects of transforming growth factor-beta on collagen synthesis by normal rat kidney epithelial cells. Am J Pathol 140:45-55, 1992
11. ZIYADEH FN, SHARMA K, ERICKSEN M, et al: Stimulation of collagen gene-expression and protein-synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth-factor-beta. J Clin Invest 93:536-542, 1994
12. SINGH R, SONG RH, ALAVI N, et al: High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta(1). Exp Nephrol 9:249-257, 2001
13. EDDY AA: Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 283:F209-F220, 2002
14. REROLLE JP, HERTIG A, NGUYEN G, et al: Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 58:1841-1850, 2000
15. EDGTTON KL, Gow RM, KELLY DJ, et al: Plasmin is not protective in experimental renal interstitial fibrosis. Kidney Int 66:68-76, 2004
16. ODA T, JUNG YO, KIM HS, et al: PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60:587-596, 2001
17. HERTIG A, BERROU J, ALLORY Y, et al: Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. FASEB J 17:1904-1906, 2003
18. LUND LR, RICCIO A, ANDREASEN PA, et al: Transforming growth-factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen-activator inhibitor messenger-RNA in Wi-38 human lung fibroblasts. EMBO J 6:1281-1286, 1987
19. TOMOOKA S, BORDER WA, MARSHALL BC, et al: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 42:1462-1469, 1992
20. HAMANO K, IWANO M, AKAI Y, et al: Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis 39:695-705, 2002
21. YOSHIDA Y, SHIIKI H, IWANO M, et al: Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome. Nephron 88:24-29, 2001
22. CHUANG-TSAI S, SISSON TH, HATTORI N, et al: Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am J Pathol 163:445-452, 2003
23. EITZMAN DT, MCCOY RD, ZHENG XX, et al: Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97:232-237, 1996
24. HUANG Y, HARAGUCHI M, LAWRENCE DA, et al: A mutant, non-inhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 112:379-388, 2003
25. CARMELIET P, KIECKENS L, SCHOONJANS L, et al: Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 92:2746-2755, 1993
26. STERIO DC: The unbiased estimation of number and sizes of arbitrary particles using the dissector. J Microsc 134:127-136, 1984
27. GUNDERSEN HJG: Stereology of arbitrary particles - A review of unbiased number and size estimators and the presentation of some new ones, in memory of Thompson, William R. J Microsc 143:3-45, 1986
28. NYENGAARD JR: Stereologic methods and their application in kidney research. J Am Soc Nephrol 10:1100-1123, 1999
29. GUNDERSEN HJG, JENSEN TB, OSTERBY R: Distribution of membrane thickness determined by linear analysis. J Microsc 113:27-43, 1978
30. RASCH R, MOGENSEN CE: Urinary excretion of albumin and total protein in normal and streptozotocin diabetic rats. Acta Endocrinol (Copenh) 95:376-381, 1980
31. DANIELSEN CC, ANDREASSEN TT: Mechanical-properties of rat tail tendon in relation to proximal distal sampling position and age. J Biomech 21:207-212, 1988
32. MINAMIDE LS, BAMBURG JR: A filter-paper dye-binding assay for quantitative determination of protein without interference from reducing agents or detergents. Anal Biochem 190:66-70, 1990
33. DE ALBUQUERQUE DA, SAXENA V, ADAMS DE, et al: An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis. Kidney Int 65:846-859, 2004
34. KJELDSEN L, JOHNSEN AH, SENGELOV H, et al: Isolation and primary structure of Ngal, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268:10425-10432, 1993
35. DANIELSEN CC, WRIGGERS H, ANDERSEN HR: Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J Mol Cell Cardiol 30:1431-1442, 1998
36. GALIS ZS, SUKHOVA GK, LIBBY P: Microscopic localization of active proteases by in situ zymography - Detection of matrix metalloproteinase activity in vascular tissue. FASEB J 9:974-980, 1995
37. KITCHING AR, KONG YZ, HUANG XR, et al: Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol 14:1487-1495, 2003
38. LOPEZ-ALEMANY R, REDONDO JM, NAGAMINE Y, et al: Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alpha v beta 3 integrin for vitronectin binding. Eur J Blochem 270:814-821, 2003
39. SCAEFIDI AK, MOODLEY YP, WEICHSELBAUM M, et al: Regulation of human lung fibroblast phenotype and function by vitronectin and vitronectin integrins. J Cell Sci 114:3507-3516, 2001
40. YANG JW, SHULTZ RW, MARS WM, et al: Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 110:1525-1538, 2002
41. NISHIDA M, FUJINAKA H, MATSUSAKA T, et al: Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 110:1859-1868, 2002
42. GONG R, RIFAI A, TOLBERT EM, et al: Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J Am Soc Nephrol 14:3047-3060, 2003
43. MARTI HP, LEE L, KASHGARIAN M, et al: Transforming growth factor-beta-1 stimulates glomerular mesangial cell synthesis of the 72-Kd type-Iv collagenase. Am J Pathol 144:82-94, 1994
44. ZHENG F, STRIKER GE, ESPOSITO C, et al: Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. Kidney Int 54:1999-2007, 1998